LBA53 A phase II, randomised, open-label study of gemcitabine/carboplatin first-line chemotherapy in combination with or without the antisense oligonucleotide apatorsen (OGX-427) in advanced squamous cell lung cancers.
Authors
Schmid, PBlackhall, Fiona H
Muthukumar, D
Lester, J
Khan, S
Adams, J
Illsley, M
Macgregor, C
Owadally, W
Sarker, S-J
Smith, L
Prendergast, A
Ackerman, C
Mousa, K
Farah, L. Lim
Affiliation
Centre for Experimental Cancer Medicine, Barts Cancer Institute-Queen MaryIssue Date
2017-09
Metadata
Show full item recordCitation
LBA53 A phase II, randomised, open-label study of gemcitabine/carboplatin first-line chemotherapy in combination with or without the antisense oligonucleotide apatorsen (OGX-427) in advanced squamous cell lung cancers. 2017, 28(suppl_5): Ann OncolJournal
Annals of OncologyDOI
10.1093/annonc/mdx440.056Additional Links
http://academic.oup.com/annonc/article/doi/10.1093/annonc/mdx440.056/4109968/LBA53A-phase-II-randomised-openlabel-study-ofType
Meetings and ProceedingsLanguage
enISSN
0923-75341569-8041
ae974a485f413a2113503eed53cd6c53
10.1093/annonc/mdx440.056